Nhwa Starts China Trial of Novel IV Opioid Analgesic
publication date: Jul 8, 2021
Jiangsu Nhwa Pharma has enrolled the first patient in a Phase III trial for Olinvyk (oliceridine) injection, a novel IV analgesic. Nhwa in-licensed China rights to the painkiller from Trevena, a Philadelphia company. Olinvyk, which was approved in the US in 2020, is an intravenous opioid analgesic indicated for acute pain that is not treated by alternative drugs. Founded in 1978, Nhwa is a China pharma focused exclusively on CNS drugs. Its products address anesthesiology, psychiatry and neurology needs. More details....
Stock Symbols: (SHZ: 2262) (NSDQ: TRVN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.